NOVIGO

NOVIGO Pharma Inc. is a Japan-based company focusing on the development of advanced healthcare solutions utilizing proprietary nanoparticle delivery technology for cosmetics and pharmaceuticals. Founded in 2021 and headquartered in Fukuoka-shi, Japan, NOVIGO Pharma Inc. specializes in innovative healthcare solutions.

The company has engaged in one funding deal, with its most recent transaction occurring on May 12, 2026. The firm has not undergone any significant pivots or changes in its core business operations since its inception. NOVIGO Pharma株式会社 specializes in the development of innovative healthcare solutions through its proprietary nanoparticle delivery technology. The company’s core offerings include advanced cosmetic products and transdermal patches that leverage next-generation percutaneous absorption technology to enhance the delivery of active ingredients.

These products aim to improve user experience and effectiveness in both cosmetic and pharmaceutical applications, thereby addressing various health and wellness needs. NOVIGO Pharma’s target customer base includes both individual consumers and healthcare providers, focusing on markets that prioritize advanced skincare and drug delivery solutions. The company's products are primarily marketed in Japan, with strategic aspirations to expand into other regions that value biotechnological innovations in healthcare. The revenue model for NOVIGO Pharma株式会社 is shaped around direct-to-consumer sales as well as business-to-business partnerships with healthcare institutions and cosmetic retailers.

The company generates income through the sale of its flagship products, which include proprietary nanoparticle delivery systems designed for both cosmetic and pharmaceutical applications. Transactions typically involve bulk orders from healthcare providers or retail partners, who then sell these products to end users. Pricing structures for these offerings are designed to reflect the advanced technology and research that underpin their development, aligning with the health and wellness market's expectations for quality and effectiveness. With a focus on fostering partnerships within the biotech sector, NOVIGO Pharma aims to enhance its market presence and drive revenue growth through strategic collaborations.

In May 2026, NOVIGO raised an undisclosed amount of Series B funding from new investors JIC Venture Growth Investments, SPARX Group, and Sagin Capital & Consulting. The funding will be utilized to strengthen operations, expand the cosmetics business, continue research on delivery technology, and support commercialization growth. The company is actively designing and launching new products aimed at enhancing its offerings and plans to expand its market reach beyond Japan into other regions that prioritize advanced biotechnological healthcare solutions.